JMP Securities is out with a bullish call on Akamai (AKAM), Canaccord Genuity cut its price target on shares of Autodesk (ADSK) and Jefferies slashed its target price on shares of teen apparel retailer Aeropostale (ARO). JMP Securities upgraded shares of Akamai Technologies to MARKET OUTPERFORM from MARKET PERFORM and added an $85 price target on the shares, that’s about a 21-percent upside from where they are currently trading. Jefferies said that Akamai is the leading content delivery network vendor where they have more than half of the market as clients. JMP also said Akamai is well positioned to take advantage of the burgeoning online and mobile video viewing trend. Akamai has also expanded its total available market significantly. Canaccord Genuity lowered its price target on shares of Autodesk. Canaccord said that as the company shifts to a cloud business model, the worse the legacy business starts to look. They also said the company is taking important steps that will evolve the business to a more predictable, higher-margin business. And, Jefferies said it is maintaining it’s hold rating on Aeropostale but lowered its price target for the shares from $2.50 to $1.25 each. Jefferies said that even though the teen retailer missed second quarter expectations, the company is clearing the decks and moving through old product to make way for new merchandise under its revamped strategy. But, Jefferies said it’s still too early to call a turn in the business.
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.
Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation.
If you have questions, please contact us here.